Browse > Article
http://dx.doi.org/10.4196/kjpp.2020.24.2.165

Changes in plasma lipoxin A4, resolvins and CD59 levels after ischemic and traumatic brain injuries in rats  

Jung, Jun-Sub (Institute of Natural Medicine, College of Medicine, Hallym University)
Kho, A Ra (Department of Physiology, College of Medicine, Hallym University)
Lee, Song Hee (Department of Physiology, College of Medicine, Hallym University)
Choi, Bo Young (Department of Physiology, College of Medicine, Hallym University)
Kang, Shin-Hae (Department of Pharmacology, College of Medicine, Hallym University)
Koh, Jae-Young (Department of Neurology, Asan Medical Center, University of Ulsan College of Medicine)
Suh, Sang Won (Department of Physiology, College of Medicine, Hallym University)
Song, Dong-Keun (Department of Pharmacology, College of Medicine, Hallym University)
Publication Information
The Korean Journal of Physiology and Pharmacology / v.24, no.2, 2020 , pp. 165-171 More about this Journal
Abstract
Ischemic and traumatic brain injuries are the major acute central nervous system disorders that need to be adequately diagnosed and treated. To find biomarkers for these acute brain injuries, plasma levels of some specialized pro-resolving mediators (SPMs, i.e., lipoxin A4 [LXA4], resolvin [Rv] E1, RvE2, RvD1 and RvD2), CD59 and interleukin (IL)-6 were measured at 0, 6, 24, 72, and 168 h after global cerebral ischemic (GCI) and traumatic brain injuries (TBI) in rats. Plasma LXA4 levels tended to increase at 24 and 72 h after GCI. Plasma RvE1, RvE2, RvD1, and RvD2 levels showed a biphasic response to GCI; a significant decrease at 6 h with a return to the levels of the sham group at 24 h, and again a decrease at 72 h. Plasma CD59 levels increased at 6 and 24 h post-GCI, and returned to basal levels at 72 h post-GCI. For TBI, plasma LXA4 levels tended to decrease, while RvE1, RvE2, RvD1, and RvD2 showed barely significant changes. Plasma IL-6 levels were significantly increased after GCI and TBI, but with different time courses. These results show that plasma LXA4, RvE1, RvE2, RvD1, RvD2, and CD59 levels display differential responses to GCI and TBI, and need to be evaluated for their usefulness as biomarkers.
Keywords
CD59; Ischemic brain injury; Lipoxin A4; Resolvins; Traumatic brain injury;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Schmued LC, Hopkins KJ. Fluoro-Jade B: a high affinity fluorescent marker for the localization of neuronal degeneration. Brain Res. 2000;874:123-30.   DOI
2 Jing L, He Q, Zhang JZ, Li PA. Temporal profile of astrocytes and changes of oligodendrocyte-based myelin following middle cerebral artery occlusion in diabetic and non-diabetic rats. Int J Biol Sci. 2013;9:190-9.   DOI
3 Loane DJ, Kumar A, Stoica BA, Cabatbat R, Faden AI. Progressive neurodegeneration after experimental brain trauma: association with chronic microglial activation. J Neuropathol Exp Neurol. 2014; 73:14-29.   DOI
4 Souza DG, Fagundes CT, Amaral FA, Cisalpino D, Sousa LP, Vieira AT, Pinho V, Nicoli JR, Vieira LQ, Fierro IM, Teixeira MM. The required role of endogenously produced lipoxin A4 and annexin-1 for the production of IL-10 and inflammatory hyporesponsiveness in mice. J Immunol. 2007;179:8533-43.   DOI
5 Marcheselli VL, Hong S, Lukiw WJ, Tian XH, Gronert K, Musto A, Hardy M, Gimenez JM, Chiang N, Serhan CN, Bazan NG. Novel docosanoids inhibit brain ischemia-reperfusion-mediated leukocyte infiltration and pro-inflammatory gene expression. J Biol Chem. 2003;278:43807-17.   DOI
6 Chou SH, Robertson CS; Participants in the International Multidisciplinary Consensus Conference on the Multimodality Monitoring. Monitoring biomarkers of cellular injury and death in acute brain injury. Neurocrit Care. 2014;21 Suppl 2:S187-214.
7 Mrozek S, Dumurgier J, Citerio G, Mebazaa A, Geeraerts T. Biomarkers and acute brain injuries: interest and limits. Crit Care. 2014;18:220.   DOI
8 Barden AE, Moghaddami M, Mas E, Phillips M, Cleland LG, Mori TA. Specialised pro-resolving mediators of inflammation in inflammatory arthritis. Prostaglandins Leukot Essent Fatty Acids. 2016;107:24-9.   DOI
9 Dalli J, Kraft BD, Colas RA, Shinohara M, Fredenburgh LE, Hess DR, Chiang N, Welty-Wolf K, Choi AM, Piantadosi CA, Serhan CN. The regulation of proresolving lipid mediator profiles in baboon pneumonia by inhaled carbon monoxide. Am J Respir Cell Mol Biol. 2015;53:314-25.   DOI
10 Perucci LO, Santos PC, Ribeiro LS, Souza DG, Gomes KB, Dusse LM, Sousa LP. Lipoxin A4 is increased in the plasma of preeclamptic women. Am J Hypertens. 2016;29:1179-85.   DOI
11 Kimberley FC, Sivasankar B, Paul Morgan B. Alternative roles for CD59. Mol Immunol. 2007;44:73-81.   DOI
12 Bazan HA, Lu Y, Jun B, Fang Z, Woods TC, Hong S. Circulating inflammation-resolving lipid mediators RvD1 and DHA are decreased in patients with acutely symptomatic carotid disease. Prostaglandins Leukot Essent Fatty Acids. 2017;125:43-7.   DOI
13 Barden A, Shinde S, Phillips M, Beilin L, Mas E, Hodgson JM, Puddey I, Mori TA. The effects of alcohol on plasma lipid mediators of inflammation resolution in patients with Type 2 diabetes mellitus. Prostaglandins Leukot Essent Fatty Acids . 2018;133:29-34.   DOI
14 Dilek F, Ozceker D, Guler EM, Ozkaya E, Yazici M, Tamay Z, Kocyigit A, Guler N. Plasma lipoxin A4 levels in childhood chronic spontaneous urticaria. Turk J Pediatr. 2018;60:527-34.   DOI
15 Vakeva A, Lehto T, Takala A, Meri S. Detection of a soluble form of the complement membrane attack complex inhibitor CD59 in plasma after acute myocardial infarction. Scand J Immunol. 2000;52:411-4.   DOI
16 McClain C, Cohen D, Phillips R, Ott L, Young B. Increased plasma and ventricular fluid interleukin-6 levels in patients with head injury. J Lab Clin Med. 1991;118:225-31.
17 Fassbender K, Rossol S, Kammer T, Daffertshofer M, Wirth S, Dollman M, Hennerici M. Proinflammatory cytokines in serum of patients with acute cerebral ischemia: kinetics of secretion and relation to the extent of brain damage and outcome of disease. J Neurol Sci. 1994;122:135-9.   DOI
18 Beamer NB, Coull BM, Clark WM, Hazel JS, Silberger JR. Interleukin-6 and interleukin-1 receptor antagonist in acute stroke. Ann Neurol. 1995;37:800-5.   DOI
19 Tuttolomondo A, Di Raimondo D, di Sciacca R, Pinto A, Licata G. Inflammatory cytokines in acute ischemic stroke. Curr Pharm Des. 2008;14:3574-89.   DOI
20 Kossmann T, Hans VH, Imhof HG, Stocker R, Grob P, Trentz O, Morganti-Kossmann C. Intrathecal and serum interleukin-6 and the acute-phase response in patients with severe traumatic brain injuries. Shock. 1995;4:311-7.   DOI
21 Aisiku IP, Yamal JM, Doshi P, Benoit JS, Gopinath S, Goodman JC, Robertson CS. Plasma cytokines IL-6, IL-8, and IL-10 are associated with the development of acute respiratory distress syndrome in patients with severe traumatic brain injury. Crit Care. 2016;20:288.   DOI
22 Suh SW, Shin BS, Ma H, Van Hoecke M, Brennan AM, Yenari MA, Swanson RA. Glucose and NADPH oxidase drive neuronal superoxide formation in stroke. Ann Neurol. 2008;64:654-63.   DOI
23 Hong DK, Choi BY, Kho AR, Lee SH, Jeong JH, Kang BS, Kang DH, Park KH, Suh SW. Carvacrol attenuates hippocampal neuronal death after global cerebral ischemia via inhibition of transient receptor potential melastatin 7. Cells. 2018;7:E231.
24 Choi BY, Lee SH, Choi HC, Lee SK, Yoon HS, Park JB, Chung WS, Suh SW. Alcohol dependence treating agent, acamprosate, prevents traumatic brain injury-induced neuron death through vesicular zinc depletion. Transl Res. 2019;207:1-18.   DOI
25 Choi BY, Jang BG, Kim JH, Lee BE, Sohn M, Song HK, Suh SW. Prevention of traumatic brain injury-induced neuronal death by inhibition of NADPH oxidase activation. Brain Res. 2012;1481:49-58.   DOI